BioPharma Drive: Drug Pricing

MAY 13, 2024

The deal — worth $100 million up front and potentially billions more later on — gives Takeda an exclusive option to license an Alzheimer’s vaccine and other “active immunotherapies.”

Licensing 78

Licensing Licensing Vaccine 78

Drugs.com

APRIL 10, 2024

WEDNESDAY, April 10, 2024 -- Teenagers suffering from anxiety, depression or bipolar disorder are likely to have a tougher time getting their driver’s license, a new study finds.Teens and young adults with these types of mood disorders are 30%.

Licensing 79

Licensing Licensing 79

Perficient: Drug Development

AUGUST 13, 2024

Cost Management and Optimization One of the key advantages of cloud migration is the potential for significant cost savings and licensing cost avoidance. Our team continuously monitors and optimizes your infrastructure, helping you to maximize the return on your cloud investment.

Licensing 52

Licensing Licensing 52

Drug Patent Watch

JULY 26, 2023

While answering a question for a DrugPatentWatch user, the question arose of technologies the NIH has licensed. It turns out that they keep a list on their website, so I… The post List of NIH-Licensed Technologies appeared first on DrugPatentWatch - Make Better Decisions.

Licensing 52

Licensing Licensing 52

BioPharma Drive: Drug Pricing

AUGUST 6, 2024

Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.

Licensing 131

Licensing Licensing Drugs 131

Drug Discovery Today

DECEMBER 2, 2020

Sanyou signs two commercial-use licenses for Horizon’s gene-edited CHO-K1 GS knockout cell line, for use in biotherapeutic pipeline development and contract research services

Licensing 113

Licensing Licensing Research 113

BioPharma Drive: Drug Pricing

MAY 16, 2024

The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.

Licensing 142

Licensing Licensing Drugs Pharmaceuticals 142

Perficient: Drug Development

OCTOBER 20, 2023

While it proved to be tricky to find an opening for an infant, we endeavored to compare in-home daycares and licensed facilities. In contrast, the licensed facilities we used maintained extended afternoon hours, providing a tad more flexibility for evening pickups. Luckily, Perficient is very family friendly.

Licensing 52

Licensing Licensing Doctors Regulations 52

FDA Law Blog: Biosimilars

FEBRUARY 5, 2024

HP&M has been helping clients navigate the challenges of state licensing regulations for drugs, biologics, medical devices, OTCs, 503B outsourcing facilities, 503A pharmacies, foods, dietary supplements, cannabis, and wholesalers/distributors for many years. Keup has joined the firm to assist attorneys Karla L.

Licensing 45

Licensing Licensing Pharmacy Regulations 45

BioPharma Drive: Drug Pricing

JULY 3, 2024

The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like its cancer vaccines.

Vaccine 67

Vaccine Licensing Licensing 67

Drug Discovery Today

JULY 7, 2022

Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapiesAgreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercializationAccess (..)

Licensing 100

Licensing Licensing Vaccine DNA 100

Drug Discovery Today

JANUARY 26, 2022

a leading provider of integrated drug discovery services to life science organisations globally, is delighted that Professors Daniel Longley, Tim Harrison and colleagues at Queen’s University Belfast have entered into a collaboration and licensing agreement with Ipsen. Saffron Walden, 26th January 2022 / Domainex Ltd.,

Licensing 100

Licensing Licensing Science Research 100

Drug Discovery World

JANUARY 17, 2024

ERS Genomics, a CRISPR/Cas9 licensing company, and StemSight, a biotechnology company developing stem cell based therapies for corneal blindness, have entered a non-exclusive CRISPR/Cas9 license agreement. The company provides licensing for companies interested in pursuing CRISPR/Cas9’s use in their commercial programmes.

Therapies 130

Therapies Licensing Licensing Laboratories 130

BioPharma Drive: Drug Pricing

FEBRUARY 1, 2024

The agreement gives Protagonist an experienced hand in Takeda, which can help the former commercialize its product.

Licensing 111

Licensing Licensing Production Drugs 111

Drug Discovery Today

APRIL 22, 2020

Cambridge, UK, and Brisbane, CA, 21 April 2020 Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license (..)

Licensing 100

Licensing Licensing Engineering Therapies 100

The Pharma Data

AUGUST 5, 2020

AstraZeneca has signed a licensing deal with UK-based biotech company Redx Pharma for its fibrotic disease candidate RXC006. Following the out licensing agreement, AZ will take RXC006 into clinical development, and will focus on evaluating the asset in a number of fibrotic disease including IPF. Source link.

Licensing 52

Licensing Licensing Clinical Trials Clinical Development 52

Drug Discovery World

AUGUST 16, 2024

biomarker targeted therapy licensed in Britain The UK Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Astellas’ Vyloy (zolbetuximab), an anti-claudin 18.2 First claudin 18.2 monoclonal antibody.

Licensing 147

Licensing Licensing Drugs Clinical Trials 147

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Therapies Pharmaceutical Companies 52

Drug Discovery World

APRIL 17, 2024

Biotechnology company Arvinas has entered into an exclusive strategic license agreement with Novartis for ARV-766, Arvinas’ second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. Arvinas will receive an upfront payment in the aggregate amount of $150 million.

Licensing 130

Licensing Licensing Clinical Development Treatment 130

The Pharma Data

JANUARY 12, 2021

13, 2021 /PRNewswire/ — EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. EVOQ Therapeutics today announced a license and collaboration agreement with Amgen. ANN ARBOR, Mich. ,

Licensing 52

Licensing Licensing Biosimilars Clinical Development 52

Crown Bioscience

MAY 2, 2024

This post delves into some frequently asked questions about Omni Screen ™ and its unique capabilities in providing compliant, large-scale cell line screening solutions that are not only cutting-edge but also aligned with industry standards and regulations.

Licensing 52

Licensing Licensing Research Regulations 52

BioPharma Drive: Drug Pricing

NOVEMBER 13, 2023

With the deal, the Swiss pharma is exploring a tumor target, DLL3, that’s thwarted past drugmaker efforts to attack it.

Licensing 75

Licensing Licensing Therapies 75

The Pharma Data

OCTOBER 27, 2021

NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders.

Licensing 52

Licensing Licensing Disease Small Molecule 52

The Pharma Data

MARCH 9, 2022

Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets.

Licensing 52

Licensing Licensing Therapies Disease 52

Drug Patent Watch

SEPTEMBER 2, 2020

The post Finding hidden treasures in old drugs: the challenges and importance of licensing generics appeared first on DrugPatentWatch - Make Better Decisions. This paper was originally published by Melek Simsek, Berrie Meijer, Adriaan A. van Bodegraven, Nanne K.H. de Boer, and Chris J.J.

Licensing 52

Licensing Licensing Drugs 52

The Pharma Data

JUNE 14, 2023

Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology Bayer and Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced an exclusive license agreement to develop and commercialize Cedilla Therapeutics’ CyclinE1/CDK2 complex inhibitors (..)

Licensing 40

Licensing Licensing Small Molecule Science 40

The Pharma Data

MARCH 31, 2023

AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc. i for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancers. CMG901 is currently being evaluated in a Phase I trial for the treatment of Claudin 18.2-positive

Licensing 40

Licensing Licensing Small Molecule Drugs 40

Drug Discovery World

JULY 1, 2024

The company partners, acquires, or in-licenses drugs from biotechs and pharma companies and develops those programmes past clinical proof of concept. The company plans to allocate the new capital towards two primary objectives: acquiring and in-licensing candidate drugs and expanding their AI capabilities.

Pharma Companies 147

Pharma Companies Licensing Licensing Drugs 147

Drug Discovery World

JULY 21, 2023

Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries.

Research 246

Research Licensing Licensing Drugs 246

Drug Discovery World

JANUARY 5, 2023

Synaffix and Hummingbird Bioscience have entered into a licensing agreement that it is hoped will enable Hummingbird Bio to develop an antibody drug conjugate (ADC) programme using Synaffix technology. .

Licensing 130

Licensing Licensing Treatment Drugs 130

Perficient: Drug Development

SEPTEMBER 3, 2024

In the wake of VMware’s recent license cost increase under Broadcom’s new pricing model, many enterprises are facing the pressing need to reevaluate their IT strategies. Licensing is a critical yet often overlooked factor in cloud migration decisions.

Licensing 52

Licensing Licensing 52

The Pharma Data

JANUARY 6, 2021

a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. LOS ANGELES , Jan. 7, 2021 /PRNewswire/ — ImaginAb Inc. , No other terms were disclosed.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

Drug Discovery World

MAY 12, 2023

The top stories: Tay licenses oral BET inhibitor to VYNE Therapeutics UK company Tay Therapeutics has entered into an exclusive license agreement with US biotech VYNE Therapeutics for its oral bromodomain and extra-terminal domain (BET) inhibitor TAY-B2.

Licensing 130

Licensing Licensing Drugs Science 130

BioPharma Drive: Drug Pricing

AUGUST 1, 2023

Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.

Licensing 52

Licensing Licensing Production Marketing 52

Drug Discovery World

SEPTEMBER 3, 2024

Grit’s non-gene-engineered TIL programme, GT101, is currently in Phase II trials and is on track to file for Biologics License Application (BLA) in 2025, making it the leading TIL pipeline in China. The company raised over $60 million in a Series B financing round in September 2023 to support development of this programme.

Engineering 147

Engineering Therapies FDA Trials 147

Drug Discovery World

AUGUST 21, 2024

Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

BioPharma Drive: Drug Pricing

JULY 10, 2023

The pharma company will pay $30 million upfront to gain rights to an experimental therapy meant to enhance the anti-tumor effect of radiation.

Licensing 56

Licensing Licensing Pharma Companies Treatment 56